Novo Nordisk A/S (NVO)
| Market Cap | 376.62B |
| Revenue (ttm) | 40.47B |
| Net Income (ttm) | 14.17B |
| Shares Out | 4.45B |
| EPS (ttm) | 3.17 |
| PE Ratio | 26.58 |
| Forward PE | 23.36 |
| Dividend | $1.44 (1.70%) |
| Ex-Dividend Date | Aug 16, 2024 |
| Volume | 2,423,998 |
| Open | 84.60 |
| Previous Close | 84.03 |
| Day's Range | 83.94 - 84.98 |
| 52-Week Range | 78.17 - 148.15 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 137.50 (+61.97%) |
| Earnings Date | Feb 5, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $137.5, which is an increase of 61.97% from the latest price.
News
Novo Nordisk A/S Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" ...
Novo Nordisk says it has not yet posted details about new CagriSema trial
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a www.clinicaltrials.gov entry.
Investors in Novo Nordisk A/S Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights – NVO
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Novo Nordisk A/S
LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" ...
The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Novo Nordisk A/S
LOS ANGELES, CA / ACCESS Newswire / January 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" ...
Ozempic Receives FDA Approval To Treat Kidney Disease
The Food and Drug Administration on Tuesday approved Ozempic, the weight loss drug made by Novo Nordisk A/S NVO, for the treatment of chronic kidney disease in patients who also have type 2 diabetes.
Ozempic Approved By FDA For Kidney Disease—In Ultra-Popular Drug's Latest Approval
The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk's popular drug known for diabetes and...
US FDA approves Novo Nordisk's diabetes drug to reduce risk of worsening kidney disease
Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes a...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding its use
The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's decisio...
Novo Nordisk A/S Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / January 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo" ...
Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Novo Nordisk A/S (NYSE: NVO) be...
Novo Nordisk to cap insulin prices in Minnesota settlement
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of deceptive pricing practices, court papers on Monday show...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Coun...
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk's recent climb.
The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week's news.
Stock Market Today: Stocks Slip as Inflation Worries Rise
Concerns over price pressures are growing ahead of next week's Fed meeting.
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial.
Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy
Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.
Why Novo Nordisk surged 14% on new weight-loss drug results
Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results from early-stage trials for its once-weekly obesity treatment, amycretin.
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's (NVO) U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.
BA's $3.5B Loss, NVO Weight Loss Drug Trial, AXP Down on Strong Earnings
"It's difficult to find what we're not liking" for American Express's (AXP) earnings, says Jenny Horne. A strong report bolstered by a big holiday shopping season wasn't enough to impress investors.
S&P500: Futures Hold Steady as Twilio and Novo Nordisk Steal the Spotlight
S&P 500 futures steady after record highs. Novo Nordisk and Twilio surge, while Boeing posts $4B loss.
NVO Weight-Loss Drug Gets Positive Data
Novo Nordisk (NVO) pops on positive drug trial results. The company showed a 22% reduction in weight for obese and overweight patients after 36 weeks.